Worth reading
57In focus
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
24.4
% (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPNet Sales48,957¥ millionYear on year +24.4%Progress 54.5%
Operating profit10,164¥ millionProgress 128.7%
Ordinary income10,708¥ millionProgress 124.5%
Net income attributable to owners of the parent8,000¥ millionYear on year +698.1%Progress 123.1%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Financial position at period-end
Total assets188,106¥ million
of which net assets 153,238 ¥ millionEquity ratio 81.5%vs. prior year-end -1.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+14,192
Investment-1,985
Financials-3,605
Net change+8,602
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥59,515 million
Segment revenuePharmaceuticals ¥47,640 million (YoY +25.1%), Real Estate Business ¥1,317 million (YoY +3.4%)
Segment profitPharmaceuticals ¥9,428 million, Real Estate Business ¥735 million
Regional sales¥18,245 million (YoY +250.9%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥89,900 million
Operating profit¥7,900 million
Ordinary income¥8,600 million
Net income¥6,500 million
Factors Behind Changes in Business Performance
Overseas sales increased as a result of receiving US$70 million in milestone income upon achievement of milestones under the license agreement with J&J.
Disclosure regarding the going concern assumption
None applicable
Change in accounting policy
基準改正に伴う変更 Availableそれ以外の変更 None見積りの変更 None修正再表示 None
Material subsequent eventsAadi Bioscience, Inc. resolved to absorb KAKEN INVESTMENTS INC. on 31 December 2026, as scheduled, and Kaken Pharmaceutical resolved to absorb ARTham Therapeutics on the same date, as scheduled. Both transactions are intended to improve management efficiency and enhance corporate value by combining management resources.
Breakdown of extraordinary income (loss)Extraordinary income Other ¥0 million / Extraordinary loss Loss on disposal of property, plant and equipment ¥50 million, Impairment loss on investment securities ¥2 million
Depreciation and amortization¥1,883 million
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥48,957 million (YoY +24.4%) |
| Operating profit | ¥10,164 million |
| Ordinary income | ¥10,708 million |
| Profit attributable to owners of the parent | ¥8,000 million (YoY +698.1%) |
| Equity ratio | End of the current fiscal period 81.5 / End of previous period 82.8 |
| Total assets | ¥188,106 million |
| Net assets | ¥153,238 million |
| Cash flows from operating activities | ¥14,192 million |
| Cash flows from investing activities | ¥-1,985 million |
| Cash flows from financing activities | ¥-3,605 million |
| Cash and cash equivalents at end of period | ¥59,515 million |
| Full-year earnings forecast | Net Sales ¥89,900 million / Operating profit ¥7,900 million / Ordinary income ¥8,600 million / Net income ¥6,500 million |
| Segment revenue | Pharmaceuticals ¥47,640 million (YoY +25.1%), Real Estate Business ¥1,317 million (YoY +3.4%) |
| Segment profit | Pharmaceuticals ¥9,428 million, Real Estate Business ¥735 million |
| Regional sales | ¥18,245 million (YoY +250.9%) |
| Depreciation and amortization | ¥1,883 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Other ¥0 million / Extraordinary loss Loss on disposal of property, plant and equipment ¥50 million, Impairment loss on investment securities ¥2 million |
| Disclosure regarding the going concern assumption | None applicable |
| Change in accounting policy | Changes due to revisions to standards Available / Other changes None / Change in accounting estimate None / Restatement None |
| Material subsequent events | Aadi Bioscience, Inc. resolved to absorb KAKEN INVESTMENTS INC. on 31 December 2026, as scheduled, and Kaken Pharmaceutical resolved to absorb ARTham Therapeutics on the same date, as scheduled. Both transactions are intended to improve management efficiency and enhance corporate value by combining management resources. |
| Factors Behind Changes in Business Performance | Overseas sales increased as a result of receiving US$70 million in milestone income upon achievement of milestones under the license agreement with J&J. |
Items this document does not state (13)
Net income per shareOperating MarginRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyOrders received and order backlogImpairment lossChanges in the scope of consolidationAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the Company received US$70 million in milestone income upon achievement of milestones under the license agreement with J&J, increasing overseas sales.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.